Skip to main content
Premium Trial:

Request an Annual Quote

Variagenics Licenses Stroke-Related Gene IP to Celera Diagnostics

NEW YORK, Jan. 15-Celera Diagnostics has secured a license to Variagenics' patents on a set of polymorphisms in a gene related to thromboembolic disease risk, Variagenics said yesterday.

 

The license, which is global and non-exclusive, allows Celera Diagnostics to commercialize products that detect variations in the gene for methylenetetrahydrofolate reductase, which has been associated with cardiovascular disease, myocardial infarction and stroke.

 

Celera plans to develop analyte specific reagents and, ultimately, in vitro diagnostics.

 

The companies did not reveal financial details of the agreement.

 

The gene may also be important in central nervous system disease, osteoporosis, folic acid metabolic diseases, and cancer, and Variagenics will retain the right to develop pharmacogenomic tests for these illnesses.

 

Variagenics acquired patent rights for MTHFR from McGill University in 1999, and researchers at the university and the company have continued to work together to find pharmacogenomic markers associated with the gene.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.